Quick Answer
Raphael Pharmaceutical Inc. reported Stockholders Equity of -$1.43 million for fiscal year 2025.
Raphael Pharmaceutical Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$1.43M | -93.1% |
| 2024 | -$742.0K | -793.5% |
| 2023 | $107.0K | +0.9% |
| 2022 | $106.0K | -17.2% |
| 2021 | $128.0K | +397.7% |
| 2020 | -$43.0K | -120.7% |
| 2019 | $208.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.26M | -105.2% | -20.6% |
| June 30, 2025 | -$1.05M | -261.4% | -42.8% |
| March 31, 2025 | -$734.0K | -612.6% | +1.1% |
| December 31, 2024 | -$742.0K | -377.9% | -20.5% |
| September 30, 2024 | -$616.0K | -721.3% | -112.4% |
| June 30, 2024 | -$290.0K | -375.4% | -181.6% |
| March 31, 2024 | -$103.0K | -1044.4% | -138.6% |
| December 31, 2023 | $267.0K | +151.9% | +456.0% |
- Raphael Pharmaceutical Inc. showed a decrease of -93.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Raphael Pharmaceutical Inc.’s stockholders equity has declined by 788.9% (from $208.0 thousand to -$1.43 million).
- The most recent figure is from Raphael Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: